Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the target of a large decrease in short interest in April. As of April 30th, there was short interest totaling 16 shares, a decrease of 97.8% from the April 15th total of 719 shares. Based on an average daily trading volume, of 3,446 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently modified their holdings of AAPG. XY Capital Ltd grew its stake in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the last quarter. UBS Group AG raised its position in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter worth $391,000. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International in the 3rd quarter valued at $383,000. Finally, ABC Arbitrage SA bought a new position in Ascentage Pharma Group International in the 3rd quarter valued at $204,000.

Wall Street Analysts Forecast Growth

AAPG has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target on the stock. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $46.67.

Ascentage Pharma Group International Stock Performance

AAPG stock traded down $0.21 during midday trading on Tuesday, reaching $21.30. 10,612 shares of the company’s stock traded hands, compared to its average volume of 3,172. The company has a 50-day simple moving average of $24.01 and a two-hundred day simple moving average of $27.03. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. Ascentage Pharma Group International has a 1-year low of $19.11 and a 1-year high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million during the quarter. As a group, research analysts predict that Ascentage Pharma Group International will post -1.09 EPS for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.